SCHEMBL22491530

SCHEMBL22491530

O=C(O)N1CCC(=C(c2ccc(F)cc2)c2cccc(F)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1F P30939 2/20 0.42
▸ PTAFR P25105 1/20 0.42
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ OPRM1 P35372 4/20 0.41
▸ OPRD1 P41143 4/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ FNTA P49354 2/20 0.38
▸ FNTB P49356 2/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22491434 0.92 FNTA (0.44) HTR1FPTAFRDRD2DRD4HTR2A
SCHEMBL22773265 0.83 MEN1 (0.43) HTR1FPTAFROPRM1OPRD1KCNH2
SCHEMBL29734471 0.83 MEN1 (0.43) HTR1FPTAFROPRM1OPRD1KCNH2
SCHEMBL22491460 0.78 OPRD1 (0.47) HTR1FHTR2AHTR2CHTR2BOPRM1
SCHEMBL22491483 0.77 DRD2 (0.45) DRD2DRD4HTR2AHTR2CHTR2B
SCHEMBL29734558 0.77 MEN1 (0.44) PTAFRMEN1KMT2AKDM4E
SCHEMBL22773290 0.77 MEN1 (0.44) PTAFRMEN1KMT2AKDM4E
SCHEMBL22491472 0.75 OPRM1 (0.42) PTAFRDRD2DRD4HTR2AHTR2C
SCHEMBL3075269 0.74 GNE (0.55) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL28807272 0.73 HTR1F (0.78) HTR1FHTR2AHTR2CHTR2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 — — EP disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 — — US disclosed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392125-A1 HETEROCYCLIC COMPOUNDS LPXN, MLX, CCNY HTR1F 1523/4885PTAFR 4511/4885DRD2 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback